Pharmstandard and Access Industries-backed Neon Therapeutics has filed for a $115m initial public offering that will support a range of ongoing clinical trials.
Neon Therapeutics, a US-based immuno-oncology treatment developer backed by pharmaceutical company Pharmstandard International and conglomerate Access Industries, filed for a $115m initial public offering on Thursday.
Neon Therapeutics is developing therapeutics vaccines and T-cell therapies for cancer. Its approach relies on targeting neoantigens – antigens which are foreign to the body but present in cancer cells.
The proceeds will enable Neon to fund the ongoing clinical development of its lead candidate NEO-PV-01 and to support pre-clinical programs and research activities,…
